Hakan DEMİRDAĞ, Duygu KURTULUŞ, KAMİL ÖZDİL, Hacı Mehmet SÖKMEN

The value of serum neutrophil gelatinase associated lipocalin levels in predicting the inflammatory bowel disease patients with axial involvement.

Giriş ve Amaç: Biz, aksiyal tutulumu olan inflamatuvar barsak hastala- rının serum nötrofil jelatinaz ilişkili lipokalin düzeylerinin, aksiyal tutulu- mu olmayan inflamatuvar barsak hastaları ve sağlıklı kontrollerin serum nötrofil jelatinaz ilişkili lipokalin düzeylerinden daha yüksek olacağı hipo- tezini ileri sürdük. Böylelikle, nötrofil jelatinaz ilişkili lipokalin değerinin aksiyal tutulumu olan inflamatuvar barsak hastalığını predikte etmedeki değerini ortaya koymaya çalıştık. Gereç ve Yöntem: Çalışma, Nisan 2011 ile Mayıs 2012 tarihlerinde, inflamatuvar barsak hastalığı grubu (n=64), inflamatuvar barsak hastalığı+aksiyal tutulum grubu (n=19) ile kontrol grubunu (n=40) içeren toplam 123 olgu üzerinde gerçekleşti- rilmiştir. Aksiyal tutulumdan farklı patojeneze sahip olması nedeniyle periferik eklem tutulumlu hastaları çalışma dışında bıraktık. Kısıtlı hasta sayısı yüzünden aksiyal artropati grubunu ayıramadık. Bulgular: Grup- lara göre olguların nötrofil jelatinaz ilişkili lipokalin düzeyleri arasında istatistiksel olarak anlamlı bir farklılık bulunmaktadır (p

Serum nötrofil jelatinaz ilişkili lipokalin düzeylerinin aksiyal tutulumu olan inflamatuvar barsak hastalığını predikte etmedeki değeri

Background and Aims: We hypothesized that serum neutrophil gelati- nase-associated lipocalin levels in inflammatory bowel disease patients with axial involvement would be higher than serum neutrophil gelati- nase-associated lipocalin levels in both an inflammatory bowel disease patients group without axial involvement and in healthy controls. We therefore attempted to demonstrate the value of using neutrophil gelatinase-associated lipocalin levels to predict inflammatory bow- el disease patients with axial involvement. Material and Methods: The study was performed in a total of 123 cases between April 2011 and May 2012, and included a control group (n=40), an inflammatory bowel disease group (n=64), and an inflammatory bowel disease+axial involvement group (n=19). We excluded patients with peripheral joint involvement because of the different pathogenesis from axial involve- ment. We could not separate the axial arthropathy group due to a limited number of cases. Results: Paired comparisons were performed to determine the difference. There was a statistically significant differ- ence in the neutrophil gelatinase-associated lipocalin levels among the groups (p<0.01). The neutrophil gelatinase-associated lipocalin levels of the inflammatory bowel disease+axial involvement group was deter- mined to be significantly higher than the inflammatory bowel disease group and the control group (p=0.001; p=0.004), respectively. neutro- phil gelatinase-associated lipocalin levels in the inflammatory bowel dis- ease group were determined to be significantly higher than the control group (p=0.001). Conclusions: We recommend the identification of a diagnostic threshold value of neutrophil gelatinase-associated lipocalin as an inflammatory marker in patients with inflammatory bowel dis- ease and inflammatory bowel disease and axial joint involvement since neutrophil gelatinase-associated lipocalin levels increase in these groups and seems to be related to the severity of colonic inflammation.

PDF

___

1. Salvarani C, Fries W. Clinical features and epidemiology of spon- dyloarthritis associated with inflammatory bowel disease. World J Gastroenterol 2009;15:2449-55.
2. Yüksel I, Ataseven H, Başar O, et al. Peripheral arthritis in the course of inflammatory bowel diseases. Dig Dis Sci 2011;56:183-7.
3. de Vlam K, Mielants H, Cuvelier C, et al. Spondyloarthropathy is un- derestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol 2000;27:2860-5.
4. Danese S, Semeraro S, Papa A, et al. Extraintestinal manifes- tations in inflammatory bowel disease. World J Gastroenterol 2005;11:7227-36.
5. Panes J, Bouhnik Y, Reinisch W, et al. Joint ECCO and ESGAR evi- dence-based consensus guidelines. J Crohns Colitis 2013;7:556-85.
6. Beslek A, Onen F, Birlik M, et al. Prevalence of spondyloarthritis in Turkish patients with inflammatory bowel disease. Rheumatol Int 2009;29:955-7.
7. Fries W. Inflammatory bowel disease-associated spondyloarthropa- thies. World J Gastroenterol 2009;15:2441-2.
8. Xu S, Carlson M, Engström Å, et al. Purification and characteriza- tion of a human neutrophil lipocalin (HNL) from secondary gran- ules of human neutrophils. Scand J Clin Lab Invest 1994;54:365-76.
9. Slack AJ, McPhail MJ, Ostermann M, et al. Predicting the develop- ment of acute kidney injury in liver cirrhosis: an analysis of glomeru- lar filtration rate, proteinuria and kidney injury biomarkers. Aliment Pharmacol Ther 2013;37:989-97.
10. Cowland JB, Sørensen OE, Sehested M, Borregaard N. Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells. J Immunol 2003;171:6630-9.
11. Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelati- nase-associated lipocalin as a novel early urinary biomarker for isch- emic renal injury. J Am Soc Nephrol 2003;14:2534-43.
12. Nielsen BS, Borregaard N, Bundgaard JR, et al. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and in- flammatory bowel diseases. Gut 1996;38:414-20.
13. Jayaraman A, Roberts KA, Yoon J, et al. Identification of neutrophil gelatinase-associated lipocalin (NGAL) as a discriminatory marker of the hepatocyte-secreted protein response to IL-1 beta: a pro- teomic analysis. Biotechnol Bioeng 2005;91:502-15.
14. Makris K, Rizos D, Kafkas N, Haliassos A. Neurophil gelatinase-as- sociated lipocalin as a new biomarker in laboratory medicine. Clin Chem Lab Med 2012;50:1519-32.
15. Yang J, Goetz D, Li J, et al. An iron delivery pathway mediated by a lipocalin. Mol Cell 2002;10:1045-56.
16. Carlson M, Raab Y, Severus L, Xu S, et al. Human neutrophil lipo- calin is a unique marker of neutrophil inflammation in ulcerative colitis and proctitis. Gut 2002;50:501-6.
17. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci 2006;11:529-43.
18. Opdenakker G. On the roles of extracellular matrix remodeling by gelatinase B. Verh K Acad Geneeskd Belg 1997;59:489-514.
19. Gupta K, Shukla M, Cowland JB, et al. Neutrophil gelatinase-asso- ciated lipocalin is expressed in osteoarthritis and forms a complex with matrix metalloproteinase 9. Arthritis Rheum 2007;56:326-35.
20. Yang J, Mori K, Li JY, Barasch J. Iron, lipocalin, and kidney epithelia. Am J Physiol Renal Physiol 2003;285:F9-F18.
21. De Vos M. Review article: joint involvement in inflammatory bowel disease. Aliment Pharmacol Ther 2004;20:36-42.
22. Faustini F, Zoli A, Ferraccioli GF. Immunologic and genetic links between spondyloarthropathies and inflammatory bowel diseases. Eur Rev Med Pharmacol Sci. 2009;13:1-9.
23. De Vos M. Joint involvement associated with inflammatory bowel disease. Dig Dis 2009;27:511-5.
24. Wood NJ. Pancreas: NGAL is a potential early diagnostic and prog- nostic biomarker of severe acute pancreatitis. Nat Rev Gastroenter- ol Hepatol 2010;7:589.
25. Aydoğdu M, Gürsel G, Sancak B, et al. The use of plasma and urine neutrophil gelatinase associated lipocalin (NGAL) and Cystatin C in early diagnosis of septic acute kidney injury in critically ill patients. Dis Markers 2013;34:237-46.
26. Oberbauer R. Biomarkers: a potential route for improved diagno- sis and management of ongoing renal damage. Transplant Proc 2008;40:S44-7.
27. Devarajan P. Review: neutrophil gelatinase-associated lipocalin: a troponin-like biomarker for human acute kidney injury. Nephrology (Carlton) 2010;15:419-28.
28. Soni SS, Cruz D, Bobek I, et al. NGAL: a biomarker of acute kidney injury and other systemic conditions. Int Urol Nephrol 2010;42:141-50.
29. Yeşil A, Gönen C, Senateş E, et al. Relationship between neutro- phil gelatinase-associated lipocalin (NGAL) levels and inflammatory bowel disease type and activity. Dig Dis Sci 2013;58:2587-93.
30. Cangemi G, Storti S, Cantinotti M, et al. Reference values for uri- nary neutrophil gelatinase-associated lipocalin (NGAL) in pediatric age measured with a fully automated chemiluminescent platform. Clin Chem Lab Med 2013;51:1101-5.
31. Argyri I, Xanthos T, Varsami M, et al. The role of novel biomarkers in early diagnosis and prognosis of acute kidney injury in newborns. Am J Perinatol 2013;30:347-52.
32. Malyszko J, Tesar V, Macdougall IC. Neutrophil gelatinase-as- sociated lipocalin and hepcidin: what do they have in common and is there a potential interaction? Kidney Blood Press Res 2010;33:157-65.
33. Paragas N, Qiu A, Hollmen M, et al. NGAL-siderocalin in kidney disease. Biochim Biophys Acta 2012;1823:1451-8.